Menu
Recruiting NCT06984081

CAPA In-vitro Oocyte Maturation

No phase Interventional Infertility, Female

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: CAPA IVM.
Who it may be relevant to
Registry conditions: Infertility, Female. Basic parameters: 0 months — 50 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Hong Kong
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

In vitro oocyte maturation (IVM) is a mild-approach assisted reproductive technology (ART). Because of its simplicity, the more favorable financial implications (reduced cost) for patients, and the lower health risk profile of IVM compared to controlled ovarian stimulation (COS) in polycystic ovary syndrome (PCOS) patients, the use of IVM in selected patients may gain increasing interest. Besides its application in patients with polycystic ovaries, IVM technology may have a role in fertility preservation, where young girls and adult women are facing infertility due to gonadotoxic chemotherapeutic treatment.

Interventions

  • Procedure CAPA IVM
    In CAPA-IVM, the oocyte is treated and matured outside the woman's body, while in classical IVF, the patient is treated. As a consequence, patients undergoing CAPA-IVM are not confronted with the typical risks and burden of systemic ovarian stimulation.

Primary outcome measures

  • No. of mature oocytes [Time frame: 1 week]

Eligibility criteria

Inclusion criteria

  • Patients aged from 0-50 years old
  • Patients seek fertility preservation services
  • Patients seek oocyte retrieval services

Exclusion criteria

-Patients unable to provide consent/assent (i.e. significant psychiatric problems/cognitive delay)

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Other

Study locations

Hong Kong · 1 center
  • Prince of Wales Hospital — Hong Kong

Identifiers

NCT: NCT06984081 · CREC.2025.238

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗